Old Web
English
Sign In
Acemap
>
Paper
>
Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice
Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice
2019
Martin Kolář
Dana Duricova
Martin Bortlik
Karolína Pudilová
Veronika Hrubá
Naděžda Machková
Katarina Mitrova
Karin Malickova
Martin Lukas
Martin Vašátko
Radka Vaníčková
Milan Lukas
Keywords:
Ustekinumab
Clinical Practice
Second-line therapy
Vedolizumab
Internal medicine
Crohn's disease
Medicine
Inflammatory Bowel Diseases
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]